tradingkey.logo
tradingkey.logo
Search

Regenxbio Inc

RGNX
Add to Watchlist
13.280USD
+0.190+1.45%
Close 07/02, 13:00ETQuotes delayed by 15 min
686.54MMarket Cap
LossP/E TTM

TradingKey Stock Score of Regenxbio Inc

Currency: USD Updated: 2026-07-02

Key Insights

Regenxbio Inc's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 97 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.25.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Regenxbio Inc's Score

Industry at a Glance

Industry Ranking
97 / 387
Overall Ranking
212 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Regenxbio Inc Highlights

StrengthsRisks
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 88.87% year-on-year.
Fairly Valued
The company’s latest PE is -2.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.28M shares, decreasing 7.13% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 62.96K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.53.

Analyst Rating

Based on 13 analysts
Buy
Current Rating
26.250
Target Price
+121.89%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Regenxbio Inc?

The TradingKey Stock Score provides a comprehensive assessment of Regenxbio Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Regenxbio Inc’s performance and outlook.

How do we generate the financial health score of Regenxbio Inc?

To generate the financial health score of Regenxbio Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Regenxbio Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Regenxbio Inc.

How do we generate the company valuation score of Regenxbio Inc?

To generate the company valuation score of Regenxbio Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Regenxbio Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Regenxbio Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Regenxbio Inc.

How do we generate the earnings forecast score of Regenxbio Inc?

To calculate the earnings forecast score of Regenxbio Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Regenxbio Inc’s future.

How do we generate the price momentum score of Regenxbio Inc?

When generating the price momentum score for Regenxbio Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Regenxbio Inc’s prices. A higher score indicates a more stable short-term price trend for Regenxbio Inc.

How do we generate the institutional confidence score of Regenxbio Inc?

To generate the institutional confidence score of Regenxbio Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Regenxbio Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Regenxbio Inc.

How do we generate the risk management score of Regenxbio Inc?

To assess the risk management score of Regenxbio Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Regenxbio Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Regenxbio Inc.